This phase 2a trial tests whether the drug TB006 can safely improve motor function in people with early-stage Parkinson's disease. About 62 participants will receive either TB006 or a placebo by IV infusion. The study is double-blind, meaning neither patients nor doctors know who…
Phase: PHASE2 • Sponsor: TrueBinding, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC